Retatrutide (Triple GIP/GLP-1/Glucagon Receptor Agonist)

Overview

Retatrutide is a synthetic, fatty-acid-acylated peptide engineered to act as a combined agonist at glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It represents a research extension of the dual and single incretin-receptor agonist compounds that preceded it, and has been studied in both preclinical models and published clinical trial research on metabolic regulation. Peptide Factory supplies Retatrutide as a lyophilized powder for laboratory research.

Research Background

Acylation of the peptide backbone with a fatty-acid moiety promotes reversible albumin binding, extending its research half-life relative to native incretin hormones. Receptor-binding assays have characterized Retatrutide’s balanced activity across all three target receptors, and this triple-agonism has become a central research question in comparative incretin pharmacology: how simultaneous GIP, GLP-1, and glucagon receptor engagement affects energy expenditure and substrate metabolism relative to single- or dual-agonist compounds.

Studied Applications

Preclinical and clinical research on Retatrutide has examined:

• Energy expenditure and substrate metabolism research — animal and human research studies have investigated the combined receptor agonism’s effect on resting energy expenditure, lipid oxidation, and glucose disposal.
• Body composition research — published clinical trial data has examined changes in body weight and composition markers in research cohorts, motivating comparative interest against single- and dual-agonist incretin compounds.
• Glycemic control research — receptor-binding and functional studies have investigated Retatrutide’s effect on insulin secretion and glucagon counter-regulation in metabolic research models.

Peptide Factory’s Retatrutide is supplied strictly for laboratory research and analytical use — it is an investigational compound, not an approved therapeutic, and no dosing or administration guidance is provided.

Storage & Handling

Store lyophilized Retatrutide at -20°C, protected from light and moisture. See our storage and handling guidance for reconstitution protocols.

References

• Jastreboff, A. M. et al. “Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial.” N. Engl. J. Med. research literature.
• Coskun, T. et al. Retatrutide receptor pharmacology and preclinical metabolic research.
• Rosenstock, J. et al. GIP/GLP-1/glucagon triple agonism research review.

For Research Use Only — Not for Human Consumption.